150 related articles for article (PubMed ID: 17409512)
1. Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.
Fukushima K; Terasaka S; Haraya K; Kodera S; Seki Y; Wada A; Ito Y; Shibata N; Sugioka N; Takada K
Biol Pharm Bull; 2007 Apr; 30(4):733-8. PubMed ID: 17409512
[TBL] [Abstract][Full Text] [Related]
2. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
Fukushima K; Haraya K; Terasaka S; Ito Y; Sugioka N; Takada K
Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
[TBL] [Abstract][Full Text] [Related]
3. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
Hong Y; Kowalski KG; Zhang J; Zhu L; Horga M; Bertz R; Pfister M; Roy A
Antimicrob Agents Chemother; 2011 Dec; 55(12):5746-52. PubMed ID: 21930880
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacology, pharmacokinetic features and interactions of atazanavir].
López-Cortés LF
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():2-8. PubMed ID: 20116610
[TBL] [Abstract][Full Text] [Related]
6. Solid self-microemulsifying drug delivery system of ritonavir.
Deshmukh A; Kulkarni S
Drug Dev Ind Pharm; 2014 Apr; 40(4):477-87. PubMed ID: 23465049
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Colombo S; Buclin T; Cavassini M; Décosterd LA; Telenti A; Biollaz J; Csajka C
Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
[TBL] [Abstract][Full Text] [Related]
8. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.
Smith DE; Jeganathan S; Ray J
HIV Clin Trials; 2006; 7(1):34-8. PubMed ID: 16632461
[TBL] [Abstract][Full Text] [Related]
9. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
[TBL] [Abstract][Full Text] [Related]
10. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
von Hentig N; Kaykhin P; Stephan C; Babacan E; Stürmer M; Staszewski S; Lötsch J
Antimicrob Agents Chemother; 2008 Jun; 52(6):2273-5. PubMed ID: 18411323
[TBL] [Abstract][Full Text] [Related]
11. Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization.
Singh G; Pai RS
Expert Opin Drug Deliv; 2014 Jul; 11(7):1023-32. PubMed ID: 24820316
[TBL] [Abstract][Full Text] [Related]
12. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
14. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
15. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
16. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Gautam N; Roy U; Balkundi S; Puligujja P; Guo D; Smith N; Liu XM; Lamberty B; Morsey B; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2013 Jul; 57(7):3110-20. PubMed ID: 23612193
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
Seminari E; Guffanti M; Villani P; Gianotti N; Cusato M; Fusetti G; Galli A; Castagna A; Regazzi M; Lazzarin A
Eur J Clin Pharmacol; 2005 Aug; 61(7):545-9. PubMed ID: 16041598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]